Diabetes combo trial pulled before it even started
NCT ID NCT07172867
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study was designed to test whether adding ofirnoflast to semaglutide helps obese people with type 2 diabetes control blood sugar and lose more weight than semaglutide alone. It was a Phase 2 trial planned for about 200 participants, but it was withdrawn before anyone enrolled. No results are available.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- ofirnoflast (HT-6184) and semaglutide
- What this could lead to
- If it works, this combination could improve blood sugar control and weight loss more than semaglutide alone for people with type 2 diabetes and obesity.
- What could go wrong
- The trial was withdrawn before enrolling any participants, so no data exists. It is unclear if the combination would be safe or effective.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETES MELLITUS, TYPE 2 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Cleveland Clinic Abu Dhabi
Abu Dhabi, Abu Dhabi Emirate, United Arab Emirates
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new stomach and gut bypass surgery tackle obesity and diabetes?
- Can a Two-Drug combo tip the scales against obesity?
- Can Weight-Loss surgery change how medications work?
- Coffee grounds probiotic could reshape gut health and fight inflammation
- Can shedding pounds reboot the Heart's exercise engine?
- Can stomach surgery alter how painkillers work?